Show results for
Refine by
Cancer Related Mutations Equipment Supplied In Germany
5 equipment items found
Manufactured by:TIB Molbiol Syntheselabor GmbH based inBerlin, GERMANY
In 2005 we developed our first LightMix Kit detecting bird flu Influenza A H5N1. Since then, we have created many kits testing for different pathogens, hematology markers, genetic mutations and polymorphisms. ...
Manufactured by:Singleron Biotechnologies GmbH based inKöln, GERMANY
FocuSCOPE is a high-throughput single cell multi-omics sequencing solution that can detect both genetic variants and transcriptome from the same single cells. Thus, FocuSCOPE® provided a tool to decipher the connection between genotype and phenotype at single cell ...
Manufactured by:Sysmex Partec GmbH based inGoerlitz, GERMANY
Highly sensitive down to 0.06 % MAF, Able to detect 6 MM with 95 % confidence across all mutations (absolute quantification), High flexibility of between 2-16 samples/run, Fast TAT (2 days), Convenient software. Plasma-SeqSensei (PSS) BC RUO Kit allows for the highly sensitive and specific detection of mutations in circulating tumour DNA (ctDNA) from the plasma of patients with breast cancer. The ...
Manufactured by:MorphoSys AG based inPlanegg, GERMANY
Tulmimetostat is a second-generation EZH2 inhibitor that has been designed to achieve comprehensive target coverage through extended on-target residence time. EZH2 acts as an epigenetic writer and normally places one or more methyl groups on a histone protein, leading to the suppression of gene expression. Some cancers depend on an abnormal pattern of gene expression and re-direct EZH2 to genes ...
Manufactured by:ORYX GmbH & Co. KG based inBaldham, GERMANY
Several cancers arise from the lack of DNA mismatch repair (MMR) resulting in the accumulation of thousands of single deletions or insertions at coding microsatellites (MSI-H). These mutations lead to the inactivation of specific proteins and to the expression of frameshift peptides (FSPs). These FSPs are tumor-specific antigens, which are constantly expressed. Cancers with MSI-H mutations ...